Difference between revisions of "Toripalimab (Loqtorzi)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 11: | Line 11: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code | + | *'''Code names:''' JS001, TAB001 |
*'''Brand name:''' Tuoyi | *'''Brand name:''' Tuoyi | ||
Revision as of 21:47, 6 February 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Bladder cancer
- Esophageal squamous cell carcinoma
- Melanoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous
Also known as
- Code names: JS001, TAB001
- Brand name: Tuoyi